Organon & Co (OGN) Stock Analysis
Verdict: WATCH (do not buy)
Excessive leverage and consecutive earnings misses offset a high FCF yield, making the recent 68% rally unsustainable.
Investment score: 48/100
Analysis as of
Is Organon & Co stock worth reviewing? The TradeMates thesis
Organon's massive debt load and poor earnings execution outweigh its cash-flow generation at current price levels.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Organon & Co opportunities and risks
What speaks for OGN
- High FCF Yield (17.4%)
What speaks against OGN
- Prohibitive Leverage 5.39x Net Debt/EBITDA
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| OGN | 14.2x | 0.6x | 7.9x | 53.1% | 4.0% | 17.4% |
| INDV | 19.2x | 3.7x | 14.6x | 83.1% | 19.4% | -3.8% |
| MANE | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.2% |
| EWTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.0% |
| CURA.TO | n/a | 2.1x | 20.0x | 40.8% | -7.9% | 2.0% |
| CRNX | n/a | 201.1x | n/a | 98.9% | -2747.2% | -11.5% |
| Peer median | n/a | 2.1x | n/a | 40.8% | 0.0% | -3.8% |
Frequently asked questions about Organon & Co (OGN)
Is OGN stock a good investment?
The TradeMates model rates Organon & Co as WATCH (do not buy) with an investment score of 48/100. Organon's massive debt load and poor earnings execution outweigh its cash-flow generation at current price levels. This is algorithmic model output, not personal investment advice.
Is OGN stock a buy?
The TradeMates model verdict for OGN is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.